ESOMEPRAZOLE STRONTIUM

Amneal Pharmaceuticals, has important news that may be of considerable value to your patients taking proton pump inhibitors (PPIs) to treat gastroesophageal reflux disease (GERD). Esomeprazole therapy is now available as esomeprazole strontium delayed-release capsules 49.3 mg.

 

Esomeprazole strontium delayed-release capsules 49.3 mg provides the same dose of esomeprazole therapy as Nexium® (esomeprazole magnesium) delayed-release capsules 40 mg* and may likely deliver cost savings to adult patients. Please see Important Safety Information about esomeprazole strontium and the full Full Prescribing Information on this website.

 

Esomeprazole strontium is a pharmaceutical alternative with the same indications in adults as Nexium®; it is not approved for patients under 18 years old. Esomeprazole strontium was shown to be pharmacokinetically (Cmax and AUC) comparable to esomeprazole magnesium delayed-release capsules and was approved by the FDA based on the same adult efficacy and safety data as Nexium®.*

 

Should esomeprazole strontium not yet be available in your electronic prescribing system or you prefer to write hard copy prescriptions, Amneal is providing a convenient self-inking stamper to facilitate accurate prescribing. Click here to request a stamper.

 

For the adult patients in your practice taking Nexium® 40 mg, new esomeprazole strontium offers a pharmaceutical alternative that may likely ease the financial burden of esomeprazole therapy. Please consider esomeprazole strontium for your appropriate adult patients at the next opportunity.

 

Please see Important Safety Information and Full Prescribing Information for esomeprazole strontium delayed-release capsules 49.3 mg.